Allied Market Research
Loading...
Cart
0
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

New
New Allied Market Research

Hormone Replacement Therapy Market by Therapy Type (Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, and Progestogen Hormone Replacement Therapy), Route of Administration (Oral, Parenteral, and Others), and Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others): Global Opportunity Analysis and Industry Forecast 2020–2027

A09508
Pages: 262
Jan 2021 | 315 Views
 
Author(s) : Kishor Sherkar and Sumitra Choudhary
Tables: 120
Charts: 53
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hormone Replacement Therapy Market

Request Now !

The global hormone replacement therapy market was valued at $31,060.5 million in 2019 and is expected to reach $46,502.8 million by 2027 with a CAGR of 5.1% during the forecast period. 

Hormone replacement therapy (HRT) is the treatment with hormones to replace natural hormones when the body does not make enough. For instance, hormone replacement therapy may be given to thyroid patients and human growth hormone patients. In addition, HRT was prescribed commonly to menopausal women for the relief of their symptoms such as hot flushes, night sweats, sleep disturbances, psychological & genito-urinary problems (urinary frequency and vaginal dryness), and for the prevention of osteoporosis. Furthermore, the survey of 2,000 American women, aged 30 to 60, found that nearly 47% of the surveyed population have experienced the symptoms of a hormonal imbalance in 2019.

Hormone-Replacement-Therapy-Market,-2020-2027

Get more information on this report : Request Sample Pages

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. The implementation of lockdown has negatively impacted the hormone replacement therapy market. Furthermore, the novel coronavirus shows a wide spectrum of clinical presentations, severity, and fatality rates. Moreover, fertility treatment, post menopause has been affected during the pandemic due to evidence suggesting that falling estrogen levels could leave older women at increased risk from the disease and possibility that hormone withdrawal may accelerate COVID-19 progression.

The major factors that contribute toward the growth of the global hormone replacement therapy market include rise in prevalence of menopausal disorder and increase in awareness about post-menopausal issues among women. In addition, new launches of hormone replacement therapy are expected to notably contribute toward the hormone replacement therapy market growth. However, adverse effects of hormone replacement therapy and high cost of treatment are anticipated to hamper the market growth during the forecast period. On the contrary, the introduction of bioidentical hormone replacement therapy and leveraging telemedicine for hormone replacement therapy are expected to provide remunerative opportunity for the expansion of the global hormone replacement therapy market in the near future.

Global Horomone Replacement Therapy Market Segmentation

Depending on therapy type, the global hormone replacement therapy market is classified into estrogen hormone replacement therapy, human growth hormone replacement therapy, thyroid hormone replacement therapy, testosterone hormone replacement therapy, and progestogen hormone replacement therapy. On the basis of route of administration, the market is segmented into oral, parenteral, and others. By indication, it is classified into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, and others. On a regional level, the global hormone replacement therapy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

On the therapy type, the estrogen hormone replacement therapy segment dominated the market in 2019. This is attributed to higher use of estradiol products in women during post-menopause or hysterectomy to help them maintain the hormonal balance.

Hormone Replacement Therapy Market
By Therapy Type

Your browser does not support the canvas element.

The estrogen hormone replacement therapy segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

By route of administration, the oral segment occupied the largest hormone replacement therapy market share in 2019, and is expected to grow at the fastest rate during the forecast period. This is attributed to the fact that oral administration is the most preferred route for testosterone drugs as well as oral medication is the most common form of estrogen replacement therapy.

As per indication, the menopausal segment is attributed to display the fastest market growth during the forecast period, owing to surge in postmenopausal women population and widening menopausal window from 40 to 55 years.

Region wise, the North American market exhibited the highest growth in terms of revenue in 2019, owing to increase in launches of various generic products of hormone replacement therapy by manufacturers, upsurge in target population, and innovations in the drug delivery systems along with development of new formulations. On the other hand, the market in Asia-Pacific is expected to register the highest CAGR in terms of revenue during the forecast period, due to rise in awareness about hormone replacement therapy, alarming surge in prevalence of diabetes, and increase in focus of healthcare providers on reducing hormonal deficiencies in China, India, and Japan.

Hormone Replacement Therapy Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

North America segment held a substantial value share in 2019 and Asia-Pacific is expected to represent the fastest market growth during the forecast period.

Get more information on this report : Request Sample Pages

The global hormone replacement therapy market is highly competitive, and prominent players have adopted various strategies for garnering maximum share. The strategies include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Abbott Laboratories, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Merck KGaA, Mylan N.V. (Viatris Inc.), Novartis International AG, Novo Nordisk A/S, and Pfizer Inc.

Key Benefits For Stakeholders

  • This report entails a detailed quantitative analysis along with the current global hormone replacement therapy market trends from 2020 to 2027 to identify the prevailing opportunities along with the strategic assessment.
  • The hormone replacement therapy market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the hormone replacement therapy market.

Key Market Segments

By Therapy Type

  • Estrogen Hormone Replacement Therapy
  • Human Growth Hormone Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
  • Progestogen Hormone Replacement Therapy

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Indication

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Others 

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2019
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in prevalence of menopausal disorder
3.5.1.2.Increase in awareness about post-menopausal issues among women
3.5.1.3.Increase in new launches by key players

3.5.2.Restraints

3.5.2.1.Adverse effects of hormone replacement therapy
3.5.2.2.High cost of treatment

3.5.3.Opportunities

3.5.3.1.Alternatives of hormone replacement therapy
3.5.3.2.Telemedicine for hormone replacement therapy

3.5.4.Impact analysis

3.6.Impact analysis of COVID-19 on hormone replacement therapy market

CHAPTER 4:HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Estrogen hormone replacement therapy

4.2.1.Market size and forecast, by region
4.2.2.Market analysis, by country

4.3.Human growth hormone replacement therapy

4.3.1.Market size and forecast, by region
4.3.2.Market analysis, by country

4.4.Thyroid hormone replacement therapy

4.4.1.Market size and forecast, by region
4.4.2.Market analysis, by country

4.5.Testosterone hormone replacement therapy

4.5.1.Market size and forecast, by region
4.5.2.Market analysis, by country

4.6.Progestogen hormone replacement therapy

4.6.1.Market size and forecast, by region
4.6.2.Market analysis, by country

CHAPTER 5:HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE 
OF ADMINISTRATION

5.1.Overview

5.1.1.Market size and forecast, by product

5.2.Oral

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Parenteral

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Others

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Menopause

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Hypothyroidism

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Male hypogonadism

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

6.5.Growth hormone deficiency

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

6.6.Others

6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country

CHAPTER 7:HORMONE REPLACEMENT THERAPY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.North America market size and forecast, by therapy type
7.2.3.North America market size and forecast, by route of administration
7.2.4.North America market size and forecast, by indication
7.2.5.North America market size and forecast, by country
7.2.6.U.S.

7.2.6.1.U.S. market size and forecast, by therapy type
7.2.6.2.U.S. market size and forecast, by route of administration
7.2.6.3.U.S. market size and forecast, by indication

7.2.7.Canada

7.2.7.1.Canada market size and forecast, by therapy type
7.2.7.2.Canada market size and forecast, by route of administration
7.2.7.3.Canada market size and forecast, by indication

7.2.8.Mexico

7.2.8.1.Mexico market size and forecast, by therapy type
7.2.8.2.Mexico market size and forecast, by route of administration
7.2.8.3.Mexico market size and forecast, by indication

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Europe market size and forecast, by therapy type
7.3.3.Europe market size and forecast, by route of administration
7.3.4.Europe market size and forecast, by indication
7.3.5.Europe market size and forecast, by country
7.3.6.Germany

7.3.6.1.Germany market size and forecast, by therapy type
7.3.6.2.Germany market size and forecast, by route of administration
7.3.6.3.Germany market size and forecast, by indication

7.3.7.France

7.3.7.1.France market size and forecast, by therapy type
7.3.7.2.France market size and forecast, by route of administration
7.3.7.3.France market size and forecast, by indication

7.3.8.UK

7.3.8.1.UK market size and forecast, by therapy type
7.3.8.2.UK market size and forecast, by route of administration146
7.3.8.3.UK market size and forecast, by indication

7.3.9.Italy

7.3.9.1.Italy market size and forecast, by therapy type
7.3.9.2.Italy market size and forecast, by route of administration
7.3.9.3.Italy market size and forecast, by indication

7.3.10.Spain

7.3.10.1.Spain market size and forecast, by therapy type
7.3.10.2.Spain market size and forecast, by route of administration
7.3.10.3.Spain market size and forecast, by indication

7.3.11.Rest of Europe

7.3.11.1.Rest of Europe market size and forecast, by therapy type
7.3.11.2.Rest of Europe market size and forecast, by route of administration
7.3.11.3.Rest of Europe market size and forecast, by indication

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by therapy type
7.4.3.Asia-Pacific market size and forecast, by route of administration
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by country
7.4.6.Japan

7.4.6.1.Japan market size and forecast, by therapy type
7.4.6.2.Japan market size and forecast, by route of administration
7.4.6.3.Japan market size and forecast, by indication

7.4.7.China

7.4.7.1.China market size and forecast, by therapy type
7.4.7.2.China market size and forecast, by route of administration
7.4.7.3.China market size and forecast, by indication

7.4.8.Australia

7.4.8.1.Australia market size and forecast, by therapy type
7.4.8.2.Australia market size and forecast, by route of administration
7.4.8.3.Australia market size and forecast, by indication

7.4.9.India

7.4.9.1.India market size and forecast, by therapy type
7.4.9.2.India market size and forecast, by route of administration
7.4.9.3.India market size and forecast, by indication

7.4.10.South Korea

7.4.10.1.South Korea market size and forecast, by therapy type
7.4.10.2.South Korea market size and forecast, by route of administration
7.4.10.3.South Korea market size and forecast, by indication

7.4.11.Rest of Asia-Pacific

7.4.11.1.Rest of Asia-Pacific market size and forecast, by therapy type
7.4.11.2.Rest of Asia-Pacific market size and forecast, by route of administration
7.4.11.3.Rest of Asia-Pacific market size and forecast, by indication

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by therapy type
7.5.3.LAMEA market size and forecast, by route of administration
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by country
7.5.6.Brazil

7.5.6.1.Brazil market size and forecast, by therapy type
7.5.6.2.Brazil market size and forecast, by route of administration
7.5.6.3.Brazil market size and forecast, by indication

7.5.7.Saudi Arabia

7.5.7.1.Saudi Arabia market size and forecast, by therapy type
7.5.7.2.Saudi Arabia market size and forecast, by route of administration
7.5.7.3.Saudi Arabia market size and forecast, by indication

7.5.8.South Africa

7.5.8.1.South Africa market size and forecast, by therapy type
7.5.8.2.South Africa market size and forecast, by route of administration
7.5.8.3.South Africa market size and forecast, by indication

7.5.9.Rest of LAMEA

7.5.9.1.Rest of LAMEA market size and forecast, by therapy type
7.5.9.2.Rest of LAMEA market size and forecast, by route of administration
7.5.9.3.Rest of LAMEA market size and forecast, by indication

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BAYER AG.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.ELI LILY AND COMPANY

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.F. HOFFMANN-LA ROCHE LTD. (GENENTECH, INC.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.HISAMITSU PHARMACEUTICAL CO., INC. (NOVEN PHARMACEUTICALS, INC.)

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.MERCK KGAA

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.MYLAN N.V. (VIATRIS INC.)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.NOVARTIS INTERNATIONAL AG

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.NOVO NORDISK A/S

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PFIZER INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 02.ESTROGEN HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 03.HUMAN GROWTH HORMONE REPLACEMENT THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 04.THYROID HORMONE REPLACEMENT THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 05.TESTOSTERONE HORMONE REPLACEMENT THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 06.PROGESTOGEN HORMONE REPLACEMENT THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027 ($MILLION)
TABLE 08.ORAL HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 09.PARENTERAL HORMONE REPLACEMENT THERPAY , BY REGION, 2019-2027 ($MILLION)
TABLE 10.OTHERS HORMONE REPLACEMENT THERPAY, BY REGION, 2019-2027 ($MILLION)
TABLE 11.GLOBAL HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 12.MENOPAUSE HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.HYPOTHYROIDISM HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.MALE HYPOGONADISM HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 
2019–2027 ($MILLION)
TABLE 15.GROWTH HORMONE DEFICIENCY HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 
2019–2027 ($MILLION)
TABLE 16.OTHERS HORMONE REPLACEMENT THERAPY MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 17.HORMOE REPLACEMENT THERAPY MARKET, BY REGION, 2019–2027, ($MILLION)
TABLE 18.NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE,
 2019–2027, ($MILLION)
TABLE 19.NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019–2027, ($MILLION)
TABLE 20.NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION, 
2019–2027, ($MILLION)
TABLE 21.NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 22.U.S. HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 23.U.S. HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 24.U.S. HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 25.CANADA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 26.CANADA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 27.CANADA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 28.MEXICO HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 29.MEXICO HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 30.MEXICO HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 31.EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 32.EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019–2027, ($MILLION)
TABLE 33.EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION, 2019–2027, ($MILLION)
TABLE 34.EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 35.GERMANY HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 36.GERMANY HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 37.GERMANY HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 38.FRANCE HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 39.FRANCE HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 40.FRANCE HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 41.UK HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 42.UK HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 43.UK HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 44.ITALY HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 45.ITALY HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 46.ITALY HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 47.SPAIN HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 48.SPAIN HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 49.SPAIN HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 50.REST OF EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 51.REST OF EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 52.REST OF EUROPE HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 
2019-2027, ($MILLION)
TABLE 53.ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 54.ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019–2027, ($MILLION)
TABLE 55.ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION, 2019–2027, ($MILLION)
TABLE 56.ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 57.JAPAN HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 58.JAPAN HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 59.JAPAN HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 60.CHINA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 61.CHINA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 62.CHINA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 63.AUSTRALIA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 64.AUSTRALIA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 65.AUSTRALIA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 66.INDIA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 67.INDIA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 68.INDIA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 69.SOUTH KOREA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 70.SOUTH KOREA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 71.SOUTH KOREA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 
2019-2027, ($MILLION)
TABLE 75.LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 76.LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019–2027, ($MILLION)
TABLE 77.LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION, 2019–2027, ($MILLION)
TABLE 78.LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019–2027, ($MILLION)
TABLE 79.BRAZIL HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 2019–2027, ($MILLION)
TABLE 80.BRAZIL HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 81.BRAZIL HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 82.SAUDI ARABIA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 83.SAUDI ARABIA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 84.SAUDI ARABIA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 85.SOUTH AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 86.SOUTH AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 87.SOUTH AFRICA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 88.REST OF LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE, 
2019–2027, ($MILLION)
TABLE 89.REST OF LAMEA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 
2019-2027, ($MILLION)
TABLE 90.REST OF LAMEA HORMONE REPLACEMENT THERAPY MARKET BY INDICATION, 2019-2027, ($MILLION)
TABLE 91.ABBOTT: COMPANY SNAPSHOT
TABLE 92.ABBOTT: OERATING SEGMENT
TABLE 93.ABBOTT: PRODUCT PORTFOLIO
TABLE 94.BAYER: COMPANY SNAPSHOT
TABLE 95.BAYER: OPERATING SEGMENTS
TABLE 96.BAYER: PRODUCT PORTFOLIO
TABLE 97.ELI LILLY: COMPANY SNAPSHOT
TABLE 98.ELI LILLY: OPERATING SEGMENTS
TABLE 99.ELI LILLY: PRODUCT PORTFOLIO
TABLE 100.ROCHE : COMPANY SNAPSHOT
TABLE 101.ROCHE: OPERATING SEGMENTS
TABLE 102.ROCHE: PRODUCT PORTFOLIO
TABLE 103.HISAMITSU: COMPANY SNAPSHOT
TABLE 104.HISAMITSU: OPERATING SEGMENTS
TABLE 105.HISAMITSU: PRODUCT PORTFOLIO
TABLE 106.MERCK: COMPANY SNAPSHOT
TABLE 107.MERCK: OPERATING SEGMENTS
TABLE 108.MERCK: PRODUCT PORTFOLIO
TABLE 109.MYLAN: COMPANY SNAPSHOT
TABLE 110.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 111.MYLAN: PRODUCT PORTFOLIO
TABLE 112.NOVARTIS: COMPANY SNAPSHOT
TABLE 113.NOVARTIS: OPERATING SEGMENTS
TABLE 114.NOVARTIS: PRODUCT PORTFOLIO
TABLE 115.NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 116.NOVO NORDISK A/S: OERATING SEGMENT
TABLE 117.NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 118.PFIZER: COMPANY SNAPSHOT
TABLE 119.PFIZER: OERATING SEGMENT
TABLE 120.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL HORMONE REPLACEMENT THERAPY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2015–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2015–2020
FIGURE 06.LOW BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ESTROGEN HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY,
 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF HUMAN GROWTH HORMONE REPLACEMENT THERAPY, BY COUNTRY,  
2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF THYROID HORMONE REPLACEMENT THERAPY, BY COUNTRY, 
2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF TESTOSTERONE HORMONE REPLACEMENT THERAPY, BY COUNTRY,  
2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PROGESTOGEN HORMONE REPLACEMENT THERAPY, BY COUNTRY, 
 2019 & 2027 (%)
FIGURE 18.COMPARATIVE COUNTRY ANALYSIS OF ORAL HORMONE REPLACEMENT THERPAY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE COUNTRY ANALYSIS OF PARENTERAL HORMONE REPLACEMENT THERPAY , 
2019 & 2027 (%)
FIGURE 20.COMPARATIVE COUNTRY ANALYSIS OF OTHERS HORMONE REPLECEMENT THERPAY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF MENOPAUSE HORMONE REPLACEMENT THERAPY MARKET, 
BY COUNTRY,  2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF HYPOTHYROIDISM HORMONE REPLACEMENT THERAPY MARKET , 
BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF MALE HYPOGONADISM HORMONE REPLACEMENT THERAPY MARKET, 
BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF GROWTH HORMONE DEFICIENCY HORMONE REPLACEMENT THERAPY
 MARKET, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF OTHERS HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY, 
 2019 & 2027 (%)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.BAYER: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 31.BAYER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 32.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 34.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 35.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 36.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 37.HISAMITSU: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.HISAMITSU: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 39.HISAMITSU: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 40.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.NOVO NORDISK A/S: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 50.NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

 
 

The hormone replacement therapy market is expected to witness profitable growth in the near future. Increase in prevalence of menopausal disorder, rise in awareness about post-menopausal signs along with the available treatment options among women, and new product launches of hormone replacement therapy are the prominent factors fostering the hormone replacement therapy market growth.

Mounting prevalence of menopausal disorder, increasing awareness regarding post-menopausal signs & the treatment options among women, and new product launches of hormone replacement therapy across the word promote the market growth.

On the contrary, alternatives to HRT include adopting lifestyle measures (regular exercise, healthy diet, cutting down on harmful food & beverages and smoking), antidepressants, tibolone, and clonidine are anticipated to limit the market growth during the forecast period. In addition, adverse effects associated with hormone replacement therapy as well as its high cost hinder the market growth.

The price of the hormones alone can range from $45-$150 per month. This cost includes high-quality medications, customized treatment plans, and follow-up appointments. The cost of the therapy for oral HRT ranges from $130 to $240 per month, to US$ 1,560 to US$ 2,440 annually. However, as most insurance companies pay for HRT pills, the cost reduces to an average of $30 per month to $360 per year. Moreover, annual individual unit costs for various treatments ranged from $47.45 to $591.30 per year for oral estrogens, $357.76 to $657.80 for transdermal estrogens, $474.50 to $803.00 for combined therapies, and $73.00 to $1,193.55 for non-hormonal prescription therapies. 

As per the analysis in the report, the market in Asia-Pacific is expected to display highest growth rate due to rise in awareness about hormone replacement therapy among public, development of healthcare infrastructure, surge in prevalence of diabetes population, and increase in focus of healthcare providers on reducing hormonal deficiencies in the developing Asian countries such as China and India.
 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Top companies such as, Mylan N.V. (Viatris Inc.), Novo Nordisk A/S, Abbott Laboratories, Pfizer Inc., and Bayer AG held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Estrogen hormone replacement therapy segment is the most influencing segment owing higher use of estradiol products in women during post-menopause or hysterectomy and to help them maintain the hormonal balance.

A. Major factors that fuels the growth of the global hormone replacement therapy market include rise in prevalence of menopausal disorder and increase in awareness about post-menopausal issues among women. In addition, new launches of hormone replacement therapy are expected to notably contribute toward the market growth. users. In addition, rise in awareness among the healthcare service provider regarding hygiene and advancements in technology are further uplifting the growth of the market

A. The total market value ofhormone replacement therapy market is $31,060.5 million in 2019.

A. The forcast period for hormone replacement therapy market is 2020-2027.

A. The market value of hormone replacement therapy market in 2027 is $46,502.8 million

A. The base year is 2019 in hormone replacement therapy market.

A. Asia-Pacific has the highest growth rate in the market which is growing this is owing to rise in awareness about hormone replacement therapy, alarming surge in prevalence of diabetes, and increase in focus of healthcare providers on reducing hormonal deficiencies in China, India, and Japan.

A. Hormone replacement therapy is medication that contains female hormones used to replace the estrogen, when the body stops making during menopause.

A. Hormone replacement therapy (HRT) is a treatment used to relieve symptoms of the menopause, hypothyroidism, male hypogonadism, and growth hormone deficiency. HRT replaces hormones such as estrogen hormone, human growth hormone, thyroid hormone, testosterone hormone, and progestogen hormone that are at a lower level in the body.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Hormone Replacement Therapy Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers